Single Dose, Two-stage Bioequivalence Study of SCMC-Lys Salt 1.35 g Powder vs SCMC-Lys Salt 90 mg/mL Syrup
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02858193|
Recruitment Status : Active, not recruiting
First Posted : August 8, 2016
Last Update Posted : August 8, 2016
|Condition or disease||Intervention/treatment||Phase|
|Bronchitis||Drug: 1.35 g SCMC- lys powder Drug: Fluifort® syrup||Phase 1|
Hide Detailed Description
As a part of the Dompé farmaceutici S.p.A. extension line program, Dompé developed a new 1.35 g powder for oral solution formulation of carbocysteine L-lysine salt-monohydrate.
The present bioequivalence phase I study is needed to compare the bioavailability and the concentration-time profile of the new 1.35 g powder for oral solution formulation with the reference compound Fluifort® 90 mg/mL syrup (15 mL corresponding to 1.35 g of SCMC- lys).
The new 1.35 g powder for oral solution formulation of carbocysteine L-lysine salt- monohydrate is expected to be bioequivalent to Fluifort® 90 mg/mL syrup with the same indications: mucolytic, expectorant in acute and chronic respiratory tract disorders.
Primary end-point is to evaluate the bioequivalent rate (Cmax) and extent (AUC0-t) of absorption of carbocysteine after single oral administration of test and reference.
Secondary end-point are:
- To describe the pharmacokinetic (PK) profile of carbocysteine after single oral administration of test and reference;
- to collect safety and tolerability data after single oral administration of test and reference.
The trial has been designed in agreement with the "Guideline on the investigation of bioequivalence." Due to the lack of information about the PK profile of the new formulation it was decided to use a "two stage" bioequivalence study design, that allows a re-calculation of the sample size in case the number of subjects initially enrolled in the study is not large enough to provide a reliable answer to the questions addressed due to underestimation of the variability or misleading estimation of the point estimate for the T/R ratio of the geometric means.
The sample size of stage 1 was calculated assuming a point estimate for the T/R ratio of the geometric means of 1.053 (i.e. μR=0.95·μT) and a multiplicative coefficient of variation (CVm) of 20% for both AUC0-t and Cmax. A power of 90% was considered and, according to the Pocock spending function and to the current European bioequivalence guideline, the α level was set to 0.0294. Fifteen (15) subjects per sequence (i.e. 30 subjects overall) will be enrolled in the first stage of the study.
After the end of study stage 1, PK parameters will be calculated and an ad interim bioequivalence test will be performed on the calculated PK parameters Cmax, AUC0-t and AUC0-∞. To safeguard the overall type I error, the α level of the bioequivalence test will be set to 0.0294 according to the Pocock spending function. Should bioequivalence be proven with the results of the subjects of the first stage, the primary objective of the study would then be satisfied and the second study stage will not take place. Should bioequivalence not be proven with the results of the subjects of the first stage and with an a posteriori calculated power > 90% for both AUC0-t and Cmax, the study will be stopped and the bioequivalence will not be proven.
Should bioequivalence not be proven with the results of the subjects of the first stage and with an a posteriori calculated power ≤ 90% for AUC0-t or Cmax, the overall sample size for the study (stage 1 plus 2) will be calculated on the basis of the ad interim bioequivalence results. The additional subjects will be enrolled into the second study stage. After completion of stage 2, the PK analysis and the bioequivalence test will be performed on the pooled subjects of the two study stages. The α level of the bioequivalence test of stage 1 plus 2 will be set to 0.0294 according to the Pocock spending function. The second stage will be performed after notification of the sample size to the local Ethics Committee and to the central Swiss authority (Swissmedic).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||Two-way Crossover, Randomised, Single Dose and Two-stage Bioequivalence Phase I Study of Carbocysteine-L-lysine Salt 1.35 g Powder for Oral Solution Formulation Versus Carbocysteine-L-lysine Salt 90 mg/mL Syrup Formulation After Oral Administration to Healthy Volunteers of Both Sexes|
|Study Start Date :||July 2016|
|Actual Primary Completion Date :||July 2016|
|Estimated Study Completion Date :||October 2016|
Experimental: 1.35 g SCMC- lys powder
1.35 g of SMC L-lysine monohydrate salt powder for solution
Drug: 1.35 g SCMC- lys powder
1.35 g SCMC- lys powder for oral solution
Other Name: Carbocisteine lysine salt 1.35 g powder for oral solution
Experimental: Fluifort® syrup
Fluifort® syrup 90 mg SCMC-lys/mL
Drug: Fluifort® syrup
SCMC-lys Syrup 90 mg/ml
Other Name: Carbocisteine lysine salt 90 mg/ml syrup
- Cmax [ Time Frame: 10 hrs ]Cmax of carbocysteine calculated from plasma concentrations after single oral dose
- AUC0-t [ Time Frame: 10 Hrs ]AUC0-t of carbocysteine calculated from plasma concentrations after single oral dose
- AUC0-∞ [ Time Frame: 10 Hrs ]AUC0-∞ of carbocysteine calculated from plasma concentrations after single oral dose
- tmax [ Time Frame: 10 Hrs ]tmax of carbocysteine calculated from plasma concentrations after single oral dose
- t1/2 [ Time Frame: 10 Hrs ]t1/2 of carbocysteine calculated from plasma concentrations after single oral dose
- TEAEs [ Time Frame: Screening ]Treatment-emergent AEs
- TEAEs [ Time Frame: 10 Hrs ]Treatment-emergent AEs
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02858193
|CROSS Research S.A., Phase I Unit|
|Arzo, Swiss, Switzerland, CH-6864|
|Principal Investigator:||Milko Radicioni, MD||CROSS Research S.A., Phase I Unit|